Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.38)
# 2,521
Out of 5,124 analysts
40
Total ratings
55.56%
Success rate
-2.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Outperform | $38 → $36 | $19.56 | +84.05% | 1 | Dec 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $89 → $94 | $78.99 | +19.00% | 4 | Dec 9, 2025 | |
| VERA Vera Therapeutics | Maintains: Outperform | $75 → $97 | $50.64 | +91.55% | 1 | Dec 8, 2025 | |
| EVMN Evommune | Initiates: Outperform | $40 | $17.12 | +133.64% | 1 | Dec 1, 2025 | |
| FBRX Forte Biosciences | Initiates: Outperform | $65 | $27.27 | +138.36% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $840.95 | +8.21% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.83 | +665.03% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $228.49 | -2.84% | 5 | Sep 22, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.02 | +147.52% | 1 | Apr 29, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $13.39 | +71.77% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $15 → $6 | $2.19 | +173.97% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $179 → $170 | $21.52 | +689.96% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $5.40 | +270.37% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $201 → $206 | $246.54 | -16.44% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $3.01 | +630.90% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $1.91 | +423.56% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $79.00 | -24.05% | 1 | Oct 5, 2022 |
Dyne Therapeutics
Dec 15, 2025
Maintains: Outperform
Price Target: $38 → $36
Current: $19.56
Upside: +84.05%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $89 → $94
Current: $78.99
Upside: +19.00%
Vera Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $75 → $97
Current: $50.64
Upside: +91.55%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $17.12
Upside: +133.64%
Forte Biosciences
Nov 25, 2025
Initiates: Outperform
Price Target: $65
Current: $27.27
Upside: +138.36%
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $840.95
Upside: +8.21%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.83
Upside: +665.03%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $228.49
Upside: -2.84%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.02
Upside: +147.52%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $13.39
Upside: +71.77%
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.19
Upside: +173.97%
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $21.52
Upside: +689.96%
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $5.40
Upside: +270.37%
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $246.54
Upside: -16.44%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $3.01
Upside: +630.90%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $1.91
Upside: +423.56%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $79.00
Upside: -24.05%